Eli Lilly and Company $LLY Stock Position Lifted by Silphium Asset Management Ltd

Silphium Asset Management Ltd lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 8.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,777 shares of the company’s stock after acquiring an additional 370 shares during the quarter. Eli Lilly and Company comprises about 1.3% of Silphium Asset Management Ltd’s investment portfolio, making the stock its 25th biggest holding. Silphium Asset Management Ltd’s holdings in Eli Lilly and Company were worth $3,724,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company in the first quarter worth approximately $27,000. Financial Gravity Companies Inc. acquired a new stake in Eli Lilly and Company during the 2nd quarter worth about $31,000. Blume Capital Management Inc. increased its holdings in shares of Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after purchasing an additional 14 shares during the period. IMG Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company in the second quarter worth approximately $35,000. Finally, TD Capital Management LLC boosted its stake in shares of Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after buying an additional 31 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 3.6%

Shares of NYSE:LLY opened at $1,109.09 on Wednesday. The company has a market capitalization of $1.05 trillion, a PE ratio of 72.49, a P/E/G ratio of 1.21 and a beta of 0.43. The company’s fifty day moving average is $869.19 and its 200-day moving average is $792.66. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,111.11.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s revenue was up 53.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Analyst Upgrades and Downgrades

LLY has been the subject of several recent research reports. The Goldman Sachs Group boosted their target price on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research report on Friday, October 10th. Morgan Stanley increased their price target on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an “overweight” rating in a report on Monday. Truist Financial raised their price target on Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the company a “buy” rating in a research report on Wednesday, November 19th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Finally, Guggenheim restated a “buy” rating and set a $948.00 price target on shares of Eli Lilly and Company in a research note on Thursday, October 16th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $1,047.50.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.